boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification Industry Update: Interim 503A and 503B Bulks Lists New Revisions FDA Schedules July 2026 PCAC Review of BPC 157, TB 500, MOTs C, KPV, Semax, Epitalon, DSIP PeptideRundown